Wof are anti diabetic agents that acts by increasing insulin sensitivity, and so should be euglycemics
Thiazolidinedione (PPARg agonist) Pioglitazone:- Only one thiazolidinedione Pioglitazone is currently available. Mech of action:- This class of oral antidiabetic drugs are selective agonists for the nuclear peroxisome proliferator-activated receptor g (PPARg) which is expressed mainly in fat cells, but also in muscle and some other cells. It enhances the transcription of several insulin responsive genes. Glitazones tend to reverse insulin resistance by enhancing GLUT4 expression and translocation. Entry of glucose into muscle and fat is improved. Hepatic gluconeo- genesis is also suppressed. Activation of genes regulating fatty acid metabolism and lipogenesis in adipose tissue contributes to the insulin sensitizing action. Lipolysis and plasma fatty acid levels are reduced. Adipocyte turnover and differentiation is accelerated by glitazones. Thus, fatty tissue is a major site of their action. Improved glycaemic control results inlowering of circulating HbA1C and insulin levels in type 2 DM patients. Pioglitazone, in addition, lowers serum triglyceride level and raises HDL level without much change in LDL level, probably because it acts on PPARa as well to induce expression of reverse cholesterol transpoer and some apoproteins. Monotherapy with glitazones is not associated with hypoglycaemic episodes. Ref:- kd tripathi; pg num:-276,277
Phenformin
Pioglitazone
Sitagliptin
Liraglutide
Endocrinology